Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 29 peer-reviewed journal articles Updated

What Is the Parkinson's Risk With Gaucher Disease?

At a Glance

If you have Type 1 Gaucher disease, your risk of Parkinson's disease is elevated due to the GBA1 gene mutation, but over 90% of patients will never develop it. Standard Gaucher treatments do not reduce this risk, so regular neurological screenings are recommended to monitor for early signs.

In this answer

4 sections

01

The Genetic Link: The GBA1 Gene

02

What Influences the Risk?

03

Do Gaucher Treatments Protect the Brain?

04

What You Should Do

If you have Type 1 Gaucher disease, you have likely heard that it comes with an increased risk of developing Parkinson’s disease. Hearing this can be incredibly frightening. However, it is essential to look at the actual numbers: over 90% of people with Type 1 Gaucher disease will never develop Parkinson’s disease [1][2][3].

While the risk is undeniably higher than it is for the general public, it remains low overall. While it is completely natural to feel anxious about this link, understanding the genetics, how your treatments work, and what to watch for can help you feel more in control.

Gaucher disease is caused by mutations in the GBA1 gene, which provides instructions for making an enzyme called glucocerebrosidase [4]. This enzyme helps clear out fatty substances in your cells. In Gaucher disease, the enzyme doesn’t work well enough, leading to a buildup of waste [5].

Researchers have discovered that this same GBA1 mutation is the most common genetic risk factor for Parkinson’s disease [6][7]. The reduced enzyme activity can lead to a buildup of a protein called alpha-synuclein in the brain, which is a hallmark of Parkinson’s [4][8]. However, simply having the mutation does not mean the disease will occur; the penetrance (the likelihood that a genetic mutation will actually cause a disease) is low [9][10][11].

What Influences the Risk?

Not all Gaucher patients have the exact same risk for Parkinson’s disease. Several factors play a role:

  • Your specific genotype: Some GBA1 mutations are considered “mild” (such as the N370S mutation, which is very common in Type 1 Gaucher disease), while others are considered “severe” (such as L444P) [12][13]. Those with severe mutations generally face a higher risk than those with mild mutations [14][15][16].
  • Age: The risk of developing Parkinson’s is age-dependent. It increases as you get older, particularly after the age of 40 [17][18][19].
  • Family history: Having a blood relative with Parkinson’s disease may also factor into your personal risk profile.

If Parkinson’s disease does develop in someone with a GBA1 mutation, the age of onset tends to be slightly younger than in people who get Parkinson’s without the mutation [20][21].

Do Gaucher Treatments Protect the Brain?

A critical piece of information for managing your health is understanding how your current Gaucher therapies interact with this risk. Standard treatments for Type 1 Gaucher disease, such as Enzyme Replacement Therapy (ERT) or Substrate Reduction Therapy (SRT), do an excellent job of managing symptoms in your body, like bone pain or an enlarged spleen.

However, standard ERT does not cross the blood-brain barrier [22][23][24]. Because the medication cannot reach the brain, there is no clinical evidence that these standard therapies reduce the risk of developing Parkinson’s disease [25][23]. It is important not to assume that being on ERT protects you from neurological risks.

There is hope, though: GBA-associated Parkinson’s disease is a highly active area of research. Ongoing clinical trials are actively testing new brain-penetrating medications (like targeted small molecules and gene therapies) specifically designed to address this risk [26][27][28].

What You Should Do

Because the vast majority of people with Type 1 Gaucher disease will not develop Parkinson’s, you do not need to live in fear of it. However, because the risk is elevated, standard medical care involves regular monitoring [17].

  • Regular Neurological Check-ins: Your care team should include a neurologist or a Gaucher specialist who performs routine neurological screenings. For many patients, an annual neurological exam is sufficient, though your doctor will recommend a schedule tailored to your age and genotype [17].
  • Watch for Early Non-Motor Symptoms: Parkinson’s disease often begins with subtle signs long before any tremors appear. These early indicators, called prodromal markers, can include a loss of the sense of smell (known medically as hyposmia or anosmia), acting out dreams during sleep (REM sleep behavior disorder), severe constipation, or noticeable mood changes like depression or anxiety [17][21][29].

If you notice any of these early signs, mention them to your doctor. Regular check-ins are sufficient to catch any changes early, allowing you to focus on living your life with confidence.

Common questions in this guide

Are Bisphosphonates Safe for Gaucher Disease Bone Loss?Do ERT or SRT Treat Gaucher Neurological Symptoms?Does Gaucher Disease Cause Growth Delays?Can Treatment Reverse Bone Damage in Gaucher Disease?How Is a Gaucher Disease Bone Crisis Treated in the ER?Will My Child Inherit Gaucher Disease?Do You Need a Bone Marrow Biopsy for Gaucher Disease?Is Gaucher Disease Treatment Safe During Pregnancy?Is There a Cure or Gene Therapy for Gaucher Disease?Should Children With Gaucher Disease Avoid Contact Sports?Should Ashkenazi Jews Get Gaucher Carrier Screening?Gaucher Disease: Do I Need Multiple Myeloma Screening?What Is Oculomotor Apraxia in Type 3 Gaucher Disease?What Blood Tests Are Used to Monitor Gaucher Disease?Why is a CYP2D6 Test Needed for Gaucher Disease SRT?
Will everyone with Gaucher disease develop Parkinson's disease?
No. Over 90% of people with Type 1 Gaucher disease will never develop Parkinson's disease. While the risk is higher than it is for the general public, it remains low overall.
How does my specific GBA1 mutation affect my Parkinson's risk?
Your risk depends partly on whether you have a mild or severe GBA1 mutation. Severe mutations, such as L444P, generally carry a slightly higher risk than mild mutations like N370S.
Do Gaucher disease treatments like ERT lower the risk of Parkinson's?
Standard treatments like Enzyme Replacement Therapy (ERT) manage bodily symptoms but do not cross the blood-brain barrier. Because of this, standard therapies do not reduce the risk of developing Parkinson's disease.
What early signs of Parkinson's disease should I watch for?
Early warning signs, known as prodromal markers, can appear long before tremors. These include a reduced sense of smell, vivid acting out of dreams during sleep, severe constipation, and noticeable mood changes like anxiety or depression.

Questions for Your Doctor

4 questions

  • •What is my specific GBA1 genotype, and how does it affect my personal risk for developing Parkinson's disease?
  • •Should I be seeing a neurologist specializing in movement disorders annually, or is routine screening by my Gaucher specialist sufficient for now?
  • •Given my age and health status, what specific early non-motor symptoms should I be monitoring for?
  • •Are there any clinical trials for brain-penetrating therapies or preventative treatments that I might be eligible for?

Questions for You

4 questions

  • •Have I experienced any new or unusual symptoms recently, such as a reduced sense of smell, vivid dreams where I move around, or chronic constipation?
  • •Do I have any blood relatives who have been diagnosed with Parkinson's disease or a related movement disorder?
  • •Do I know the exact name of my GBA1 gene mutation so I can accurately discuss my risk profile?
  • •Is my anxiety about developing Parkinson's disease affecting my daily life, and should I seek support to help manage it?

References

References (29)
  1. 1

    Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.

    Gatto EM, Da Prat G, Etcheverry JL, et al.

    Brain sciences 2019; (9(2)) doi:10.3390/brainsci9020030.

    PMID: 30717266
  2. 2

    Epidemiology of Gaucher Disease in France: Trends in Incidence, Mortality, Management, and Complications Over Three Decades.

    Nguyen Y, Beydon M, Yousfi K, et al.

    Journal of inherited metabolic disease 2025; (48(3)):e70037 doi:10.1002/jimd.70037.

    PMID: 40348574
  3. 3

    Gaucher disease and comorbidities: B-cell malignancy and parkinsonism.

    Cox TM, Rosenbloom BE, Barker RA

    American journal of hematology 2015; (90 Suppl 1()):S25-8 doi:10.1002/ajh.24057.

    PMID: 26096744
  4. 4

    Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

    Alcalay RN, Levy OA, Waters CC, et al.

    Brain : a journal of neurology 2015; (138(Pt 9)):2648-58 doi:10.1093/brain/awv179.

    PMID: 26117366
  5. 5

    Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations.

    Abeliovich A, Hefti F, Sevigny J

    Journal of Parkinson's disease 2021; (11(s2)):S183-S188 doi:10.3233/JPD-212739.

    PMID: 34151863
  6. 6

    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.

    Avenali M, Cerri S, Ongari G, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(5)):1267-1272 doi:10.1002/mds.28496.

    PMID: 33617695
  7. 7

    GBA1-associated parkinsonism: new insights and therapeutic opportunities.

    Ryan E, Seehra G, Sharma P, Sidransky E

    Current opinion in neurology 2019; (32(4)):589-596 doi:10.1097/WCO.0000000000000715.

    PMID: 31188151
  8. 8

    A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.

    Kinghorn KJ, Grönke S, Castillo-Quan JI, et al.

    The Journal of neuroscience : the official journal of the Society for Neuroscience 2016; (36(46)):11654-11670 doi:10.1523/JNEUROSCI.4527-15.2016.

    PMID: 27852774
  9. 9

    Gaucher disease provides a unique window into Parkinson disease pathogenesis.

    Hertz E, Chen Y, Sidransky E

    Nature reviews. Neurology 2024; (20(9)):526-540 doi:10.1038/s41582-024-00999-z.

    PMID: 39107435
  10. 10

    Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations.

    Lopez G, Eisenberg DP, Gregory MD, et al.

    Annals of neurology 2020; (87(4)):652-657 doi:10.1002/ana.25692.

    PMID: 32030791
  11. 11

    Glucocerebrosidase and its relevance to Parkinson disease.

    Do J, McKinney C, Sharma P, Sidransky E

    Molecular neurodegeneration 2019; (14(1)):36 doi:10.1186/s13024-019-0336-2.

    PMID: 31464647
  12. 12

    Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers.

    Menozzi E, Schapira AHV

    Frontiers in neurology 2021; (12()):694764 doi:10.3389/fneur.2021.694764.

    PMID: 34248830
  13. 13

    Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

    Liu G, Boot B, Locascio JJ, et al.

    Annals of neurology 2016; (80(5)):674-685 doi:10.1002/ana.24781.

    PMID: 27717005
  14. 14

    Clinical Variability and Genotype-Phenotype Correlation in Spanish Patients with Type 1 Gaucher Disease: A Focus on Non-c.[1226A>G]; [1448T>C] Genotypes.

    Serrano-Gonzalo I, Bauza F, Lopez de Frutos L, et al.

    International journal of molecular sciences 2025; (26(20)) doi:10.3390/ijms262010088.

    PMID: 41155380
  15. 15

    The N370S/R496H genotype in type 1 Gaucher disease - Natural history and implications for pre symptomatic diagnosis and counseling.

    Zeid N, Stauffer C, Yang A, et al.

    Molecular genetics and metabolism reports 2020; (22()):100567 doi:10.1016/j.ymgmr.2020.100567.

    PMID: 32042592
  16. 16

    Insights into the structural biology of Gaucher disease.

    Smith L, Mullin S, Schapira AHV

    Experimental neurology 2017; (298(Pt B)):180-190 doi:10.1016/j.expneurol.2017.09.010.

    PMID: 28923368
  17. 17

    Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1.

    Wilke MVMB, Dornelles AD, Schuh AS, et al.

    Orphanet journal of rare diseases 2019; (14(1)):103 doi:10.1186/s13023-019-1079-4.

    PMID: 31077260
  18. 18

    Parkinsonism in Patients with Neuronopathic (Type 3) Gaucher Disease: A Case Series.

    Ryan E, Amato D, MacKenzie JJ, et al.

    Movement disorders clinical practice 2020; (7(7)):834-837 doi:10.1002/mdc3.13031.

    PMID: 33043079
  19. 19

    Penetrance of Parkinson's disease in GBA1 carriers depends on variant severity and polygenic background.

    Hassanin E, Landoulsi Z, Pachchek S, et al.

    NPJ Parkinson's disease 2025; (11(1)):162 doi:10.1038/s41531-025-00997-y.

    PMID: 40506446
  20. 20

    Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.

    Tayebi N, Parisiadou L, Berhe B, et al.

    Molecular genetics and metabolism 2017; (122(4)):198-208 doi:10.1016/j.ymgme.2017.11.001.

    PMID: 29173981
  21. 21

    Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum.

    Potnis KC, Flueckinger LB, DeArmey SM, et al.

    Molecular genetics and metabolism reports 2018; (17()):69-72 doi:10.1016/j.ymgmr.2018.10.001.

    PMID: 30364808
  22. 22

    White vitreous opacities in five patients with Gaucher disease type 3.

    Seehra GK, Eghbali A, Sidransky E, FitzGibbon E

    American journal of medical genetics. Part A 2020; (182(4)):808-812 doi:10.1002/ajmg.a.61479.

    PMID: 31898869
  23. 23

    Pharmacotherapy of Gaucher Disease: Current and Future Options.

    Bennett LL, Fellner C

    P & T : a peer-reviewed journal for formulary management 2018; (43(5)):274-309.

    PMID: 29719368
  24. 24

    Animal Models for the Study of Gaucher Disease.

    Cabasso O, Kuppuramalingam A, Lelieveld L, et al.

    International journal of molecular sciences 2023; (24(22)) doi:10.3390/ijms242216035.

    PMID: 38003227
  25. 25

    The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

    Aflaki E, Westbroek W, Sidransky E

    Neuron 2017; (93(4)):737-746 doi:10.1016/j.neuron.2017.01.018.

    PMID: 28231462
  26. 26

    Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease.

    Han TU, Sam R, Sidransky E

    Frontiers in cell and developmental biology 2020; (8()):271 doi:10.3389/fcell.2020.00271.

    PMID: 32509770
  27. 27

    A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.

    Aflaki E, Borger DK, Moaven N, et al.

    The Journal of neuroscience : the official journal of the Society for Neuroscience 2016; (36(28)):7441-52 doi:10.1523/JNEUROSCI.0636-16.2016.

    PMID: 27413154
  28. 28

    The use of Ambroxol for the treatment of Gaucher disease: A systematic review.

    Abelleyra Lastoria DA, Grewal S, Hughes D

    EJHaem 2024; (5(1)):206-221 doi:10.1002/jha2.852.

    PMID: 38406552
  29. 29

    Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy.

    Kartha RV, Joers J, Terluk MR, et al.

    Journal of inherited metabolic disease 2020; (43(3)):564-573 doi:10.1002/jimd.12182.

    PMID: 31613991

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or Gaucher specialist regarding your specific genetic risks and neurological screening schedule.

Get notified when new evidence is published on Gaucher Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.